Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Guangdong Aglaia Optoelectronic Materials Co. Ltd. has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are assigned to 6 distinct examiners, indicating a high degree of individual review for each application. The portfolio spans 4 distinct art units, which suggests that the company's biological or pharmaceutical innovations fall into several different specialized categories. OTTON, ALICIA L is the busiest examiner, currently overseeing 1 busiest examiner pending action. The 6 pending office actions are distributed such that no single examiner manages more than one case.
With 4 distinct art units involved, the company faces a variety of examination perspectives within the biotechnology field. The presence of 6 distinct examiners for 6 actions highlights a lack of examiner-level consolidation in current prosecution. Practitioners should be prepared to manage 6 distinct examiners who may have different interpretations of the 6 pending office actions. This distribution across 4 distinct art units requires monitoring of different examination styles and procedural nuances. The company's strategy must account for the 6 distinct examiners while navigating the technical requirements of the 4 distinct art units. The presence of the workload across 4 distinct art units highlights the diverse technical nature of the company's current filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| GARRETT, DAWN L | 1 | 72.7% | +10.2% |
| YANG, JAY LEE | 1 | 73.8% | +2.2% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562205 | ORGANIC ELECTROLUMINESCENT MATERIALS CONTAINING B-N FUSED RINGS, AND APPLICATIONS THEREOF | HAVLIN, ROBERT H | — |
| 18562177 | HETEROCYCLIC MODIFIED PLATINUM COMPLEX CONTAINING ONCN TETRADENTATE LIGAND | GARRETT, DAWN L | — |
| 18038679 | DIVALENT PLATINUM COMPLEX | YANG, JAY LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777027 | IMIDAZOPYRIDINE-BASED ARYLAMINE COMPOUND AND USE THEREOF | MCDOWELL, BRIAN E | 28d overdue |
| 18562205 | ORGANIC ELECTROLUMINESCENT MATERIALS CONTAINING B-N FUSED RINGS, AND APPLICATIONS THEREOF | HAVLIN, ROBERT H | — |
| 18562177 | HETEROCYCLIC MODIFIED PLATINUM COMPLEX CONTAINING ONCN TETRADENTATE LIGAND | GARRETT, DAWN L | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1786 | 2 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873893 | ORGANIC ELECTROLUMINESCENT MATERIAL AND USE THEREOF | OTTON, ALICIA L | 1624 | §102 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18562205 | ORGANIC ELECTROLUMINESCENT MATERIALS CONTAINING B-N FUSED RINGS, AND APPLICATIONS THEREOF | HAVLIN, ROBERT H | 1626 | §102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18562177 | HETEROCYCLIC MODIFIED PLATINUM COMPLEX CONTAINING ONCN TETRADENTATE LIGAND | GARRETT, DAWN L | 1786 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18038679 | DIVALENT PLATINUM COMPLEX | YANG, JAY LEE | 1786 | §102§103Other | Non-Final OA | — | Pending | May 24, 2023 |
| 17777027 | IMIDAZOPYRIDINE-BASED ARYLAMINE COMPOUND AND USE THEREOF | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | 28d overdue | Pending | May 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangdong Aglaia Optoelectronic Materials Co. Ltd. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Alicia L Otton has the most, with 1 of Guangdong Aglaia Optoelectronic Materials Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
